52. Boulding R, Stacey R, Niven R, et al. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev 2016 25: 287–294. 53. Neder JA, Hirai DM, Jones JH, et al. A 56-year-old, otherwise healthy woman presenting with light-headedness and progressive shortness of breath. Chest 2016 150: e23–e27. 54. Law N, Ruane LE, Low K, et al. Dysfunctional breathing is more frequent in chronic obstructive pulmonary disease than in asthma and in health. Respir Physiol Neurobiol 2017 247: 20–23. 55. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016 134: e282–e293. 56. Laviolette L, Laveneziana P. Exercise testing in the prognostic evaluation of patients with lung and heart diseases. In: Palange P, Laveneziana P, Neder JA, et al., eds. Clinical Exercise Testing (ERS Monograph). Sheffield, European Respiraotry Society, 2018 pp. 222–234. 57. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991 83: 778–786. 58. Guazzi M, Bandera F, Ozemek C, et al. Cardiopulmonary exercise testing: what is its value? J Am Coll Cardiol 2017 70: 1618–1636. 59. Cahalin LP, Chase P, Arena R, et al. A meta-analysis of the prognostic significance of cardiopulmonary exercise testing in patients with heart failure. Heart Fail Rev 2013 18: 79–94. 60. Popovic D, Arena R, Guazzi M. A flattening oxygen consumption trajectory phenotypes disease severity and poor prognosis in patients with heart failure with reduced, mid-range, and preserved ejection fraction. Eur J Heart Fail 2018 (DOI: 10.1002/ejhf.1140). 61. Balady GJ, Arena R, Sietsema K, et al. Clinician’s guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 2010 122: 191–225. 62. Guazzi M, Arena R, Halle M, et al. 2016 Focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Eur Heart J 2016 pii: ehw180. 63. Neder JA, Alharbi A, Berton DC, et al. Exercise ventilatory inefficiency adds to lung function in predicting mortality in COPD. COPD 2016 13: 416–424. 64. Brunelli A, Belardinelli R, Pompili C, et al. Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection. Ann Thorac Surg 2012 93: 1802–1806. 65. Brunelli A. Ventilatory efficiency slope: an additional prognosticator after lung cancer surgery. Eur J Cardiothorac Surg 2016 50: 780–781. 66. Harvie D, Levett DZH. Exercise testing for pre-operative evaluation. In: Palange P, Laveneziana P, Neder JA, et al., eds. Clinical Exercise Testing (ERS Monograph). Sheffield, European Respiraotry Society, 2018 pp. 251– 279. 67. Older PO, Levett DZH. Cardiopulmonary exercise testing and surgery. Ann Am Thorac Soc 2017 14: Suppl. 1, S74–S83. 68. Levett DZH, Jack S, Swart M, et al. Perioperative cardiopulmonary exercise testing (CPET): consensus clinical guidelines on indications, organization, conduct, and physiological interpretation. Br J Anaesth 2018 120: 484–500. 69. Oudiz RJ, Roveran G, Hansen JE, et al. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail 2007 9: 917–921. 70. Guazzi M, Myers J, Peberdy MA, et al. Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. Int J Cardiol 2010 144: 410–412. 71. Tang Y, Yao L, Liu Z, et al. Effect of calcium channel blockers evaluated by cardiopulmonary exercise testing in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing. Pulm Pharmacol Ther 2017 43: 26–31. 72. Iwase T, Nagaya N, Ando M, et al. Acute and chronic effects of surgical thromboendarterectomy on exercise capacity and ventilatory efficiency in patients with chronic thromboembolic pulmonary hypertension. Heart Br Card Soc 2001 86: 188–192. 73. Charalampopoulos A, Gibbs JSR, Davies RJ, et al. Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension. J Appl Physiol 2016 121: 623–628. 74. Neuberg GW, Friedman SH, Weiss MB, et al. Cardiopulmonary exercise testing. The clinical value of gas exchange data. Arch Intern Med 1988 148: 2221–2226. 75. Palange P, Carlone S, Forte S, et al. Cardiopulmonary exercise testing in the evaluation of patients with ventilatory vs circulatory causes of reduced exercise tolerance. Chest 1994 105: 1122–1126. 76. Martinez FJ, Stanopoulos I, Acero R, et al. Graded comprehensive cardiopulmonary exercise testing in the evaluation of dyspnea unexplained by routine evaluation. Chest 1994 105: 168–174. 77. Flaherty KR, Wald J, Weisman IM, et al. Unexplained exertional limitation: characterization of patients with a mitochondrial myopathy. Am J Respir Crit Care Med 2001 164: 425–432. https://doi.org/10.1183/2312508X.10015318 xxiii